CCM
CRBP icon

Cinctive Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Cinctive Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,013
Closed -$2.22M – 412
2024
Q2 		$2.22M Buy
+49,013
New +$2.06M 0.11% 240

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cinctive Capital Management's CRBP Position: Q3 2024 in Review

Cinctive Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 49,013 shares — an estimated $2.22M sold.

Cinctive Capital Management first reported a position in CRBP in Q2 2024 and held it in 1 quarter. The position peaked at $2.22M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Cinctive Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cinctive Capital Management sold 49,013 Corbus Pharmaceuticals shares in Q3 2024, an estimated $2.22M.
  • Cinctive Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Cinctive Capital Management's Corbus Pharmaceuticals position peaked at $2.22M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Cinctive Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.